You’re not pointing out what’s missing. You’re hoping no one reads the filings.
Your claim that the EDEN unit “hasn’t even been built yet” and is “obviously not in the MAA” is flatly contradicted by NWBO’s own SEC disclosures.
From the 2025 10-K:
“We are continuing comparability testing between the products manufactured manually and the products manufactured using the Flaskworks system, in connection with the anticipated inclusion of the Flaskworks system in our regulatory applications.”
That is not speculative. That is an explicit statement of regulatory intent, worded precisely, submitted under SEC oversight, and built around an active integration plan.
From the Q1 2025 10-Q:
“We are also continuing integration of the Flaskworks EDEN system at our manufacturing site, and preparing for additional regulatory filings and inspections relating to this system.”
Integration. Inspections. Regulatory filings. These are not future ideas. They’re active processes, in motion, and reflected in formal documents governed by securities law.
This isn’t just a contradiction of your claim, it’s a directional signal. NWBO is either including Flaskworks in the current MAA or staging it for immediate post-approval deployment under a defined regulatory pathway. That’s not up for interpretation. It’s spelled out in plain language.
You also ignore that MHRA publicly disclosed inspections of U.S. manufacturing sites in 2024. DCVax-L is manufactured in the UK. There is no plausible reason for MHRA to be inspecting U.S. facilities unless Flaskworks was involved. That inspection trail aligns with the SEC disclosures and further confirms its regulatory relevance.
SI 2025 No. 87 is now in force. It creates a legal infrastructure for Control Site licensing, modular GMP systems, and named-patient labeling. The EDEN unit fits that structure with precision. That legislation didn’t appear in a vacuum. It was written to accommodate something specific.
No speculation required. The disclosures speak for themselves
Bullish
AI
Market Data 
Markets 
